Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug
Viktor Zarev
The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer. For Cytokinetics, aficamten already saw success in obstructive HCM, so the hypothesis of ACACIA-HCM was simple – can the drug help patients […] The post Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug appeared first on Cardiac Wire .